Understanding cervical cancer treatment and characteristics in Italy
RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent / Metastatic (R/M) Cervical Cancer in Italy
This study looks at how patients in Italy with advanced or recurring cervical cancer are treated and what their experiences are like.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | MSD Italia S.r.l. Industry-sponsored |
| Drugs / interventions | Pembrolizumab, Levantinib |
| Locations | 11 sites (Bologna, Bologna and 10 other locations) |
| Trial ID | NCT06771193 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the characteristics and treatment patterns of patients with locally advanced or recurrent/metastatic cervical cancer in Italy. By reviewing medical records from oncologic clinics between January 2018 and December 2021, the study will capture data on patient demographics, disease characteristics, and treatment approaches. The study will categorize patients based on risk levels and assess differences in treatment strategies. This retrospective analysis will provide valuable insights into the management of cervical cancer in the specified population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with locally advanced, recurrent, or metastatic cervical cancer who received treatment between January 2018 and December 2021.
Not a fit: Patients currently participating in pharmacological clinical trials or those treated with specific medications like Pembrolizumab, Olaparib, or Levantinib may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of cervical cancer treatment patterns, potentially leading to improved patient outcomes.
How similar studies have performed: While this study is observational and retrospective, similar studies have provided valuable insights into treatment patterns and outcomes in cancer care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF) * Age ≥18 years * Diagnosis of a cervical cancer * Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease * Any treatment received between January 2018 and December 2021 for advanced disease Exclusion Criteria: * Patients participating in a pharmacological clinical trial for the treatment of advanced disease * Patients who participated in a clinical trial * Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs
Where this trial is running
Bologna, Bologna and 10 other locations
- Oncologia Medica Policlinico Sant'Orsola Malpighi — Bologna, Bologna, Italy (Recruiting)
- Ginecologia ed Ostetricia A.O. Cannizzaro — Catania, Catania, Italy (Recruiting)
- Oncologia Medica 1 IRCCS Ospedale Policlinico San Martino — Genova, Genova, Italy (Recruiting)
- Unità di Ginecologia Oncologica Medica IRCCS Ospedale San Raffaele — Milan, Milano, Italy (Recruiting)
- Unità Ostetricia, Ginecologia e Ginecologia Oncologica medica Humanitas San Pio X — Milan, Milano, Italy (Recruiting)
- Oncologia A.O.U. di Modena - Policlinico — Modena, Modena, Italy (Recruiting)
- U.O.S. Trattamenti Innovativi dell'utero Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale — Naples, Napoli, Italy (Recruiting)
- UOC Oncologia Medica ed Ematologia Azienda Ospedaliera Universitaria Luigi Vanvitelli — Naples, Napoli, Italy (Recruiting)
- IRCCS Centro di Riferimento Oncologico (CRO) — Aviano, Pordenone, Italy (Recruiting)
- U.O.C. Ginecologia Oncologica Policlinico Agostino Gemelli — Roma, Roma, Italy (Recruiting)
- UOC Oncologia Medica Ospedale Dell'Angelo - Mestre Azienda USL3 Serenissima — Mestre, Venezia, Italy (Not_yet_recruiting)
Study contacts
- Study coordinator: Stefania Lopez
- Email: info.studiclinici@opisresearch.com
- Phone: +39 03626331
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.